看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 2.9x - 3.2x | 3.0x |
| Historical Pb Multiple | 0.0x - 7.3x | 2.0x |
| Fair Value | €14.76 - €16.31 | €15.53 |
| Upside | -31.0% - -23.8% | -27.4% |
| Benchmarks | - | Full Ticker |
| uniQure N.V. | - | NasdaqGS:QURE |
| Pharming Group N.V. | - | NasdaqGM:PHAR |
| Merus N.V. | - | NasdaqGM:MRUS |
| LAVA Therapeutics N.V. | - | NasdaqGS:LVTX |
| argenx SE | - | OTCPK:ARGN.F |
| NewAmsterdam Pharma Company N.V. | - | DB:KH6 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| QURE | PHAR | MRUS | LVTX | ARGN.F | KH6 | |||
| NasdaqGS:QURE | NasdaqGM:PHAR | NasdaqGM:MRUS | NasdaqGS:LVTX | OTCPK:ARGN.F | DB:KH6 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 30.1% | 38.5% | -129.9% | -17.3% | 726.6% | 27.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -646.6% | 4.0% | -346.7% | -453.5% | -176.6% | -854.3% | ||
| Prior Fiscal Year | -1947.1% | -4.3% | -352.6% | -618.6% | -23.3% | -1255.8% | ||
| Latest Fiscal Year | -883.4% | -4.0% | -595.9% | -209.6% | 37.1% | -530.3% | ||
| Latest Twelve Months | -1388.0% | -2.4% | -685.6% | -567.7% | 41.0% | -258.9% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -70.5% | 5.0% | -49.4% | -58.4% | -14.7% | -30.7% | ||
| Prior Fiscal Year | -90.2% | -5.0% | -51.4% | -60.9% | -8.5% | -49.3% | ||
| Latest Twelve Months | -409.8% | -3.6% | -48.5% | -90.2% | 24.7% | -28.4% | ||
| Next Fiscal Year | 185.9% | -5.5% | -15.5% | -154.1% | 16.8% | -36.2% | ||
| Two Fiscal Years Forward | 66.1% | 9.6% | -8.0% | 274.7% | 21.2% | -30.7% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 72.8x | 2.5x | 85.6x | 8.0x | 12.9x | 44.7x | ||
| Price / LTM EPS | -5.2x | -101.7x | -12.5x | -1.4x | 31.5x | -17.3x | ||
| Price / Book | -260.8x | 3.5x | 5.7x | 2.0x | 6.6x | 3.7x | ||
| Price / Fwd Book | -5.6x | 4.1x | 8.7x | 11.1x | 4.9x | 6.2x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -260.8x | 3.5x | 6.6x | |||||
| Historical P/B Ratio | 0.0x | 2.0x | 7.3x | |||||
| Selected P/B Multiple | 2.9x | 3.0x | 3.2x | |||||
| (x) Book Value | 778 | 778 | 778 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | QURE | PHAR | MRUS | LVTX | ARGN.F | KH6 | |
| Value of Common Equity | 1,044 | 866 | 4,814 | 40 | 31,792 | 3,235 | |
| (/) Shares Outstanding | 68.1 | 68.8 | 75.6 | 26.3 | 51.3 | 129.9 | |
| Implied Stock Price | 15.33 | 12.58 | 63.65 | 1.53 | 619.44 | 24.90 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 15.33 | 12.58 | 63.65 | 1.53 | 619.44 | 21.40 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |